Reference	
number(s)	
C22977-A	
C22977-A	

# Ixempra (ixabepilone)

#### **PROGRAM RATIONALE**

**Client Requested:** The intent of the criteria is to ensure that patients follow selection elements established by Clover Health for Ixempra.

### **CRITERIA FOR APPROVAL**

- 1. What is the patient's diagnosis?
  - a. Breast cancer
  - **b.** Other
- 2. Is the patient currently receiving therapy with the requested medication?

Yes

No

# Continuation criteria

3. Is the patient receiving benefit from therapy with the requested medication as defined as no evidence of unacceptable toxicity and no evidence of disease progression while on the current regimen?

Yes

No

#### Initiation criteria

20. Does the patient have human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic disease? If 'Yes', documentation of HER2 status testing results must be submitted upon request.

Yes

Nο

21. Will the requested medication be used as a single agent?

Yes

No

22. Does the patient have human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic disease? If 'Yes', documentation of HER2 status testing results must be submitted upon request.

Yes

No

23. Will the requested medication be used in combination with trastuzumab?

Yes

No

24. Will the requested medication be used for metastatic or locally advanced disease?

Yes

No

25. Has the patient tried and failed an anthracycline and a taxane?

Ixempra Clover MedB C22977-A 04-2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference	Ī
number(s)	
C22977-A	

Yes

No

26. Is the cancer taxane resistant and the patient has a contraindication to further anthracycline therapy?

Yes No

27. Does the patient have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level greater than 2.5 times the upper limit of normal (ULN) or bilirubin greater than 1 time the ULN?

Yes

No

# **SUMMARY OF EVIDENCE**

1. Ixempra [package insert]. Halle/Westfalen, Germany: Baster Oncology GmbH; February 2022.

#### **EXPLANATION OF RATIONALE**

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

Ixempra Clover MedB C22977-A 04-2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

